LOS ANGELES – ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces Wells Pharma of Houston will begin shipping limited quantities of pharmaceutical-grade Niagen^® (patented nicotinamide riboside chloride or NRC), branded Niagen+, to select IV clinics including Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness, and REVIV in August, with additional clinics set to receive shipments soon after. U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute pharmaceutical-grade intravenous (IV) and injectable Niagen, which will be available in IV, shots, and intravenous-push forms exclusively at clinics, with a prescription.

“Science-based health clinics nationwide are eager to offer Niagen IV as a superior alternative to NAD+ IV,” said Rob Fried, CEO of ChromaDex. “We welcome this group of clinics as the first to offer Niagen IV and look forward to announcing additional availability soon.”

Niagen IV represents a significant advancement in intravenous NAD+ therapy. Compared to standard NAD+ IV treatments, Niagen IV offers superior tolerability, a 75% shorter infusion time, and a higher, faster rise in NAD+ blood levels three hours post-infusion, as measured by NAD+ dried blood spot tests (MedRxiv).

Increasing interest in intravenous therapies positions Niagen+ for significant growth within the intravenous hydration therapy market, valued at over $2.32 billion globally and $1.15 billion in North America in 2022 (Grand View Research). With an order already placed by Wells Pharma of Houston securing pharmaceutical-grade Niagen for clinics beyond August and hundreds more clinics in the pipeline for the rest of the year, Niagen IV is well-situated to cover the entirety of the US intravenous hydration market with ChromaDex’s new, superior product. Additionally, with the popularity of IV and injection procedures on the rise, we see significant opportunity to further expand into categories such as medical spas, with 11,000 locations operating in the US alone, according to the American Med Spa Association.

Kris Fishman, President of Wells Pharmacy Network, said, “We are thrilled to collaborate with ChromaDex on Niagen+. Through our 503B pharmacy network, we will compound this innovative product for clinics across the U.S.”

Clean Market/NutriDrip, Next Health, REVIV, and Restore Hyper Wellness celebrate the launch of Niagen+:

• Asa Kitfield, Managing Partner at Clean Market & NutriDrip, remarked, “We are thrilled to unveil Niagen IV at Clean Market locations and The Spa by Equinox Hotels at Hudson Yards as a groundbreaking wellness solution that perfectly aligns with our commitment to enhancing health and vitality. Niagen IV offers reduced side effects and a shorter infusion time, making it more compelling than traditional NAD+ infusions. This means our clients can enjoy the benefits of enhanced cellular health and energy production with greater comfort and ease. We are confident pharmaceutical grade Niagen will become a cornerstone of our injectable wellness treatments, delivering the exceptional results our clients expect.”

• Darshan Shah, M.D., board-certified surgeon, founder of Next Health, and ChromaDex consultant, noted, “Niagen IV is a game changer, minimizing the unpleasant side effects of NAD+ IV and maximizing absorption. The approach ChromaDex has taken with their hero ingredient, nicotinamide riboside chloride (NRC), finally makes IV therapy for mitochondrial health a true reality.”

• Johnny Parvani, M.D., Founder and Chief Medical Officer of REVIV, added, “I am thrilled to launch Niagen IV and injections to our network of healthcare practitioners. Validated by extensive research, this groundbreaking product features ChromaDex’s proprietary nicotinamide riboside chloride (NRC) technology to support cellular health. At REVIV, we are committed to pioneering solutions that enhance human health for our customers. As a better alternative to NAD+ IV, we believe Niagen IV and injections will redefine the longevity wellness category, enabling healthcare providers to optimize patient outcomes with an innovation backed by the highest scientific and quality standards.”

• Rachele Pojednic, PhD, Director of Scientific Research at Restore Hyper Wellness, commented, “After completing an extensive study on Niagen IV, in partnership with ChromaDex, we are impressed by its significant potential to promote longevity and enhance overall health.”

Clinics and healthcare providers interested in offering Niagen IV and injections to patients can email ChromaDex’s Vice President of Business Development, Eric Huynh, at support@niagenplus.com. Consumers can visit www.niagenplus.com to sign up for product news and updates on future clinic availability and use the store locator to find a clinic offering Niagen IV and injections near you.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to rolling out limited quantities of pharmaceutical-grade Niagen (patented nicotinamide riboside chloride or NRC), branded Niagen+, to select IV clinics including Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness, and REVIV in August, with additional clinics set to receive shipments soon. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could” or the negative of such terms or other similar expressions, and include the statements regarding Niagen IV being available starting in August and nationwide thereafter; Niagen IV’s potential to reach the global intravenous hydration therapy and spa markets; the potential health benefits of Niagen IV; and the potential for Niagen IV to materially impact the overall NAD+ industry. These forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to the Company’s ability to secure adequate pharmaceutical grade quantities of Niagen IV in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to distribute Niagen IV to IV clinics; the Company’s ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company’s ability to maintain and enforce the Company’s existing intellectual property and obtain new patents related to Niagen IV; the Company’s ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of the Company’s products; the Company’s reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with the Company’s business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

About ChromaDex:

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor and quality in the dietary supplement space, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen^® (patented nicotinamide riboside, or NR). Clinically proven to increase NAD+ levels, Niagen is the most efficient and superior-quality NAD+ booster helping people transform the way they age.

Food-grade Niagen is manufactured by ChromaDex and is available in the consumer dietary supplement Tru Niagen^®, the number one healthy-aging oral NAD+ supplement in the United States* (available at www.truniagen.com). Pharmaceutical-grade Niagen will be available through FDA-registered 503B outsourcing facilities and will be administered at clinics pursuant to a valid prescription (www.niagenplus.com).

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.

*Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716150746/en/

ChromaDex Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

Ben Shamsian

Lytham Partners

646-829-9701

shamsian@lythampartners.com